HK1032542A1 - Combination for the treatment of alcohol dependence containing an opioid antagonist and nmda receptor complex modulator - Google Patents

Combination for the treatment of alcohol dependence containing an opioid antagonist and nmda receptor complex modulator

Info

Publication number
HK1032542A1
HK1032542A1 HK01103236A HK01103236A HK1032542A1 HK 1032542 A1 HK1032542 A1 HK 1032542A1 HK 01103236 A HK01103236 A HK 01103236A HK 01103236 A HK01103236 A HK 01103236A HK 1032542 A1 HK1032542 A1 HK 1032542A1
Authority
HK
Hong Kong
Prior art keywords
nmda receptor
receptor complex
opioid antagonist
treatment
combination
Prior art date
Application number
HK01103236A
Other languages
English (en)
Inventor
Martine Daoust
Yves Le Buclay Bonhomme
Phillipe Durbin
Original Assignee
Merck Sante Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sante Sas filed Critical Merck Sante Sas
Publication of HK1032542A1 publication Critical patent/HK1032542A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK01103236A 1998-03-26 2001-05-08 Combination for the treatment of alcohol dependence containing an opioid antagonist and nmda receptor complex modulator HK1032542A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98400723A EP0945133A1 (fr) 1998-03-26 1998-03-26 Combinaison pharmaceutique d'un antagoniste opioide et d'un modulateur du complexe récepteur de NMDA, utilisée dans le traitement de la dépendance à l'alcool ou de la toxicomanie
PCT/EP1999/002337 WO1999048500A1 (fr) 1998-03-26 1999-03-26 Combinaison destinee au traitement de la dependance a l'alcool et aux drogues contenant un antagoniste d'opioides et un modulateur du complexe du recepteur nmda

Publications (1)

Publication Number Publication Date
HK1032542A1 true HK1032542A1 (en) 2001-07-27

Family

ID=8235311

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01103236A HK1032542A1 (en) 1998-03-26 2001-05-08 Combination for the treatment of alcohol dependence containing an opioid antagonist and nmda receptor complex modulator

Country Status (18)

Country Link
US (1) US6512009B1 (fr)
EP (2) EP0945133A1 (fr)
KR (1) KR20010034678A (fr)
AT (1) ATE230993T1 (fr)
AU (1) AU758569B2 (fr)
BR (1) BR9909138A (fr)
CA (1) CA2325739C (fr)
CZ (1) CZ296367B6 (fr)
DE (1) DE69904922T2 (fr)
DK (1) DK1063995T3 (fr)
ES (1) ES2190205T3 (fr)
HK (1) HK1032542A1 (fr)
HU (1) HU226555B1 (fr)
NO (1) NO319313B1 (fr)
PL (1) PL193241B1 (fr)
RU (1) RU2226107C2 (fr)
SK (1) SK284623B6 (fr)
WO (1) WO1999048500A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8052982B2 (en) 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
BR9912275A (pt) * 1998-07-20 2001-04-17 Peptech Ltd Formulação de bioimplante
WO2001052851A1 (fr) * 2000-01-22 2001-07-26 Albert Shulman Methodes de traitement d'abus de substances
EP1262196A3 (fr) * 2001-05-23 2002-12-18 Pfizer Products Inc. Combinaison d'un inhibiteur de la recapture de monoamines et d'un antagoniste opioique pour l'utilisation dans l'alcoolisme et la dépendance alcoolique
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
ES2187288B1 (es) * 2001-09-24 2004-09-16 Garbil Pharma Investigacion Chile Ltda Aminas como agentes anti-alcoholismo.
EP1509182A4 (fr) 2002-05-31 2009-12-30 Titan Pharmaceuticals Inc Dispositif polymere implantable permettant la liberation prolongee de buprenorphine
EP1575569B1 (fr) 2002-12-13 2010-09-29 Durect Corporation Forme d'administration orale de medicaments comprenant un vehicule liquide de haute viscosite
WO2004056337A2 (fr) * 2002-12-18 2004-07-08 Pain Therapeutics Formes posologiques orales comprenant des agents actifs au plan therapeutique dans des noyaux a liberation lente et des revetements de capsule en gelatine a liberation immediate
CN1777426A (zh) * 2003-03-31 2006-05-24 泰坦医药品公司 用于持续释放多巴胺受体激动剂的可植入聚合物装置
US20050031668A1 (en) * 2003-05-30 2005-02-10 Patel Rajesh A. Implantable polymeric device for sustained release of nalmefene
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
AU2007333656A1 (en) * 2006-12-19 2008-06-26 University Of Virginia Patent Foundation Combined effects of topiramate and ondansetron on alcohol consumption
US8415401B2 (en) 2007-12-06 2013-04-09 Durect Corporation Oral pharmaceutical dosage forms
KR20100127799A (ko) 2008-02-28 2010-12-06 유니버시티 오브 버지니아 페이턴트 파운데이션 세로토닌 운반체 유전자 및 알콜중독의 치료
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
ES2664083T3 (es) 2010-07-02 2018-04-18 University Of Virginia Patent Foundation Enfoque genético molecular para el tratamiento y diagnóstico de la dependencia de alcohol y drogas
EA027743B1 (ru) 2011-09-09 2017-08-31 Юниверсити Оф Вирджиния Пэтент Фаундейшн Молекулярно-генетический подход для лечения и диагностики алкогольной и наркотической зависимости
RU2476209C1 (ru) * 2012-02-29 2013-02-27 Станислав Анатольевич Кедик Имплантируемое лекарственное средство на основе налтрексона для лечения пациентов, зависимых от алкоголя или опиатов
CN105120659A (zh) 2013-03-15 2015-12-02 度瑞公司 用于降低溶解可变性的具有流变改性剂的组合物
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
WO2023023038A1 (fr) * 2021-08-17 2023-02-23 Yale University Compositions et méthodes de traitement

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11505547A (ja) * 1996-03-13 1999-05-21 エール ユニバーシティ ナルトレキソン及び関連化合物を用いる禁煙処置

Also Published As

Publication number Publication date
KR20010034678A (ko) 2001-04-25
PL193241B1 (pl) 2007-01-31
DK1063995T3 (da) 2003-03-10
BR9909138A (pt) 2000-12-05
WO1999048500A1 (fr) 1999-09-30
EP1063995A1 (fr) 2001-01-03
HUP0101546A3 (en) 2002-10-28
EP1063995B1 (fr) 2003-01-15
EP0945133A1 (fr) 1999-09-29
DE69904922D1 (de) 2003-02-20
AU758569B2 (en) 2003-03-27
CZ20003525A3 (cs) 2001-04-11
CZ296367B6 (cs) 2006-02-15
SK284623B6 (sk) 2005-08-04
HUP0101546A2 (hu) 2001-09-28
HU226555B1 (en) 2009-03-30
NO20004788L (no) 2000-11-24
SK14282000A3 (sk) 2001-05-10
NO319313B1 (no) 2005-07-11
ATE230993T1 (de) 2003-02-15
CA2325739A1 (fr) 1999-09-30
CA2325739C (fr) 2007-05-15
PL343069A1 (en) 2001-07-30
US6512009B1 (en) 2003-01-28
AU3522699A (en) 1999-10-18
DE69904922T2 (de) 2004-01-08
NO20004788D0 (no) 2000-09-25
RU2226107C2 (ru) 2004-03-27
ES2190205T3 (es) 2003-07-16

Similar Documents

Publication Publication Date Title
HK1032542A1 (en) Combination for the treatment of alcohol dependence containing an opioid antagonist and nmda receptor complex modulator
MX9602683A (es) Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas.
HUP9900183A3 (en) Oral fast-dissolving pharmaceutical compositions for dopamine agonists
ES2181055T3 (es) Formulaciones galenicas que contienen antagonistas de opiaceos.
IL116673A (en) Stable oral pharmaceutical composition containing an acid labile benzimidazole
HUP9701694A3 (en) Indolinone derivatives for the treatment of disease, use thereof, pharmaceutical compositions containing these compounds
IL117728A0 (en) Pharmaceutical compositions for transdermal administration
EP0749751A3 (fr) Composition pharmaceutique pour utilisation dans le traitement du diabète
UA66750C2 (en) Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors
MX9605023A (es) Compuestos substituidos de imidazolidin-2,4-diona como substancias farmaceuticamente activas.
GB9917822D0 (en) Nmda antagonist
HUP0203597A3 (en) Pharmaceutical compositions containing zolmitriptan, process for their preparation and their use
CA2270177A1 (fr) Administration transdermique de 7.alpha.-methyl-19-nortestosterone ("ment")
IL101358A0 (en) Crystalline tiagabine hydrochloride monohydrate,its preparation and pharmaceutical compositions containing it
AU1549500A (en) Use of n-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis
MX9708394A (es) Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
AU2000272858A1 (en) Pharmaceutical composition for treating hyperhomocysteinaemia caused by medicaments
GB9907571D0 (en) Compounds
IL114673A (en) Pharmaceutical compositions containing protein for oral administration
AU2670600A (en) Pharmaceutical composition containing desoxypeganine for the treatment of nicotine dependence
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
NZ515685A (en) Use of riluzole for the treatment of multiple sclerosis
AU2001244999A1 (en) Naphthamide neurokinin antagonists for use as medicaments
AU2882699A (en) Stabilizing composition for pharmaceutical dosage forms

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140326